Article

Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome.

Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, UK.
Arthritis & Rheumatology (Impact Factor: 7.48). 02/2009; 60(2):619-25. DOI: 10.1002/art.24294
Source: PubMed

ABSTRACT Tumor necrosis factor receptor (TNFR)-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory condition caused by mutations in the TNFRSF1A gene. Unlike other autoinflammatory diseases in which anti-TNF therapy is largely a successful treatment option, therapy with the anti-TNF drug infliximab is often ineffective in patients with TRAPS. Moreover, in certain cases, infliximab actually triggers severe episodes of inflammation. The aim of this study was to elucidate the mechanisms underlying such a reaction.
Peripheral blood mononuclear cells (PBMCs) were obtained from patients with TRAPS. Both caspase 3 activity and NF-kappaB subunit activity were determined by enzyme-linked immunosorbent assay. Cytokine secretion was assessed using a specific customized human multiplex bead immunoassay kit.
Unlike findings in controls, cells from a family of 9 patients, all of whom carried the T50M mutation in TNFRSF1A, failed to respond to infliximab through proapoptotic induction of caspase 3 activity. Instead, we observed enhanced antiapoptotic c-Rel subunit activity, accompanied by a significant increase in secretion of the proinflammatory cytokines interleukin- 1beta (IL-1beta), IL-1 receptor, IL-6, IL-8, and IL-12.
Altered extracellular conformation of TNFRI, resulting from the T50M mutation in TNFRSF1A, results in failure of PBMCs to induce an apoptotic response to infliximab. We hypothesize that failure to shed infliximab-bound TNF/TNFRI from the cell surface of cells from patients with the T50M mutation triggers c-Rel activation, and that this leads to a marked increase in cytokine secretion and an increased proinflammatory response. In light of these findings, we strongly advise caution when prescribing infliximab as anti-TNF therapy to patients with TRAPS.

0 Bookmarks
 · 
105 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetische Fiebersyndrome oder hereditäre rekurrierende Fiebersyndrome (HRF) werden als Teil der autoinflammatorischen Erkrankungen (AID) angesehen, die auf Störungen im angeborenen (,,innate“) Immunsystem beruhen. Typisch für diese Erkrankungen sind selbstlimitierte Episoden mit Fieber und hohen Entzündungszeichen. Der Vererbungsmodus kann sowohl autosomal-rezessiv als auch autosomal-dominant sein. Die Vertreter dieser Erkrankungen sind das familiäre Mittelmeerfieber, Tumornekrosefaktorrezeptor-1-assoziiertes periodisches Syndrom, Hyper-IgD-Syndrom und Cryopyrin-assoziierte periodische Syndrome. Die als ,,deficiency of interleukin 1 receptor antagonist“ beschriebene Erkrankung gehört nur bedingt in diese Krankheitsgruppe, da das Fieber kein typisches Symptom ist. Die Therapie hängt von der Art und Schwere der Erkrankung ab. Für das familiäre Mittelmeerfieber besteht eine effektive Prophylaxe mit Colchizin. Für schwere Formen der HRF-Erkrankungen ist die Therapie mit Biologika, insbesondere die Blockade von Il-1, hocheffektiv. Mit dem Ziel, mehr Informationen über diese Erkrankungen zu dokumentieren, eine Biobank einzurichten und Forschungsprojekte zu initiieren, wurde das AID-Net-Projekt gegründet, das vom Bundesministerium für Bildung und Forschung finanziert wird. In das Register sind bisher 606 Patienten mit AID eingeschleust worden, davon haben 381 ein HRF.
    Zeitschrift für Rheumatologie 01/2013; 72(4). · 0.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), formerly known as familial Hibernian fever, is the most common autosomal dominant autoinflammatory disease, resulting from mutations in the TNFRSF1A gene, encoding the 55-kD tumor necrosis factor receptor. The pathophysiologic mechanism of TRAPS remains ambiguous and only partially explained. The onset age of the syndrome is variable and the clinical scenery is characterized by recurrent episodes of high-grade fever that typically lasts 1-3 weeks, associated with migrating myalgia, pseudocellulitis, diffuse abdominal pain, appendicitis-like findings, ocular inflammatory signs, and risk of long-term amyloidosis. Fever episodes are responsive to high-dose corticosteroids, but different classes of drugs have been reported to be ineffective. The use of etanercept is unable to control systemic inflammation, while interleukin-1 blockade has been shown as effective in the control of disease activity in many patients reported so far.
    Clinical rheumatology. 06/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The innate immune system is involved in the pathophysiology of systemic autoinflammatory diseases (SAIDs), an enlarging group of disorders caused by dysregulated production of proinflammatory cytokines, such as interleukin-1β and tumor necrosis factor-α, in which autoreactive T-lymphocytes and autoantibodies are indeed absent. A widely deranged innate immunity leads to overactivity of proinflammatory cytokines and subsequent multisite inflammatory symptoms depicting various conditions, such as hereditary periodic fevers, granulomatous disorders, and pyogenic diseases, collectively described in this review. Further research should enhance our understanding of the genetics behind SAIDs, unearth triggers of inflammatory attacks, and result in improvement for their diagnosis and treatment.
    Mediators of Inflammation 01/2014; 2014:948154. · 3.88 Impact Factor

Full-text

Download
38 Downloads
Available from
Jun 2, 2014